Related Experiment Video
Updated: Jul 19, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Novel insulin analogues and its mitogenic potential
1Department on Internal Medicine, Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX 75390-8858, USA.
Diabetes, Obesity & Metabolism
|October 10, 2006
Summary
Insulin analogues offer improved diabetes management by mimicking natural insulin secretion. This study examines the metabolic and mitogenic effects of current and upcoming insulin analogues to ensure their safety and efficacy.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Background:
- Insulin analogues are engineered to better replicate endogenous insulin secretion patterns.
- Recombinant technology allows structural modifications to alter insulin absorption kinetics, improving glycemic control.
- Structural changes may impact metabolic and mitogenic activities, raising safety concerns.
Purpose of the Study:
- To evaluate the metabolic and mitogenic characteristics of currently available insulin analogues (lispro, aspart, glargine).
- To assess emerging insulin analogues (glulisine, detemir) for their metabolic and mitogenic profiles.
- To address safety concerns regarding insulin analogue use, particularly in relation to diabetic retinopathy progression.
Main Methods:
- Analysis of structural modifications in insulin analogues using recombinant technology and site-directed mutagenesis.
- Assessment of factors influencing mitogenic potency, including receptor binding and signaling pathways.
- Review of existing studies on insulin analogue use and diabetic retinopathy progression.
Main Results:
- Insulin analogues exhibit varied metabolic and mitogenic profiles due to structural alterations.
- Concerns exist regarding potential links between specific insulin analogues and retinopathy progression, though causality remains unproven.
- Inconsistent study methodologies and confounding factors complicate the interpretation of safety data.
Conclusions:
- Understanding the metabolic and mitogenic properties of insulin analogues is crucial for safe and effective diabetes treatment.
- Further research is needed to clarify the long-term safety and clinical implications of different insulin analogues.
- Comparative analysis of insulin analogues will guide clinical decision-making and optimize patient outcomes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...